MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects

Chen, Mao; Qiu, Li Xin; Zhan, Ping; Xue, Kai; Ding, Hong; Du, Fang; Li, Jin; Chen, Qing

doi:10.1007/s00432-009-0742-x

Cited by 37 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…high Gleason sum) tumors, likely differ from risk factors for total incident prostate cancer (12). In addition, several single nucleotide polymorphisms (SNPs) in antioxidant genes have been associated with prostate cancer, and these may modify the relations between circulating or dietary antioxidants and prostate cancer (13, 14). Thus, the discrepant results for antioxidants and prostate cancer may be due to a lack of focus on clinically relevant, advanced forms of the disease or the inability to account for the impact of genetic variants on antioxidant metabolism and availability.…”

Section: Introductionmentioning

confidence: 99%

Plasma Antioxidants, Genetic Variation in SOD2, CAT, GPX1, GPX4, and Prostate Cancer Survival

Blarigan

Kenfield

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Antioxidants may reduce risk of aggressive prostate cancer, and single nucleotide polymorphisms (SNPs) in antioxidant genes may modify this association. Methods We used Cox proportional hazards regression to examine circulating prediagnostic alpha-tocopherol, gamma-tocopherol, and lycopene; SNPs in SOD2 (n=5), CAT (n=6), GPX1 (n=2), GPX4 (n=3); and their interactions and risk of lethal prostate cancer among 2,439 men with nonmetastatic prostate cancer in the Health Professionals Follow-up Study and Physicians’ Health Study. Results We observed 223 events over a median follow-up of 10 years. Higher alpha-tocopherol levels were associated with lower risk of lethal prostate cancer (hazard ratio (HR) 3rd v. 1st quartile (Q): 0.51; 95% confidence interval (CI): 0.30, 0.89; HR 4th v. 1st Q: 0.68; 95% CI: 0.41, 1.13; p-trend: 0.02). Men homozygous for the less common allele (G) at rs3746165 in GPX4 had a 35% lower risk of lethal prostate cancer compared to men homozygous for the more common allele (A) (HR: 0.65; 95% CI: 0.43, 0.99). Among men homozygous for the less common allele in rs3746165, high gamma-tocopherol levels were associated with a 3.5-fold increased risk of lethal prostate cancer (95% CI: 1.27, 9.72; p-value: 0.02; interaction p-value 0.01). Conclusions Among men with nonmetastatic prostate cancer, higher circulating prediagnostic alpha-tocopherol may be associated with lower risk of developing lethal disease. Variants in GPX4 may be associated with risk of lethal prostate cancer, and may modify the relation between gamma-tocopherol and prostate cancer survival. Impact Circulating tocopherol levels and variants in GPX4 may affect prostate cancer progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Antioxidants, Genetic Variation in SOD2, CAT, GPX1, GPX4, and Prostate Cancer Survival

Blarigan

Kenfield

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…But, the role of OS and polymorphisms of the antioxidant enzymes on carcinogenetic process has been studied extensively in recent years. [7][8][9][10] The L55M and Q192R functional polymorphisms are the two most common examples of PON1 polymorphism in the human serum that have been studied in the previous studies related with the cancer and polymorphisms. Two important mutations in 55 and 192 codons of PON1 which affect paraoxonase activities have been shown in molecular studies.…”

Section: Discussionmentioning

confidence: 99%

A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer

Uluocak

Atılgan

Parlaktaş

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: We aimed to show the relationship between paraoxonase 1 (PON1) gene polymorphism and the development of prostate cancer (PCa). Material and methods:We investigated the association of single nuclotide polymorphisms of PON1 enzyme with the development of PCa risk. A total of 147 male patients were divided into PCa, and control groups. The control group was also divided into two subgroups according to serum prostate specific antigen (PSA) levels as non PCa-high PSA (>4 ng/mL) and non PCa-low PSA (≤4 ng/mL) groups. Results:The mean ages of the patients were 64.81 years, 63.27 years and 64.22 years in PCa group, non PCalow PSA and non PCa -high PSA groups, respectively. The mean PSA levels were 10.9 ng/mL, 1.16 ng/mL and 6.63 ng/mL for PCa group, non PCa -low PSA and non PCa -high PSA groups, respectively. In terms of PON1 polymorphisms and allele frequencies, there were no statistically significant differences between PCa and control groups. There was not a statistically significant difference between PCa and non PCa-high PSA groups as for genotypic and allelic frequencies. As a result of this small sample sized hypothetical study of polymorphism, a relationship could not be detected between PCa development and PON1 gene polymorphism. Conclusion:According to the results of this preliminary study, it is thought that more comprehensive future studies are necessary to clarify the possible role of PON1 gene polymorphism in the etiology of PCa.

show abstract

“…It is thought that SNPs contribute to interindividual variability in susceptibility to common diseases such as cancer [35,36]. So far, some published meta-analyses have confirmed that a number of SNPs are associated with increased or decreased PCa risk in different races, such as A49T in steroid-5-alpha-reductase, alpha polypeptide 2 (SRD5A2) gene [37], Gly388Arg in fibroblast growth factor receptor 4 (FGFR4) gene [38], -160C/A in E-cadherin (CDH1) gene [39], Val16Ala in manganese superoxide dismutase (MnSOD) gene [40], C677T in 5,10-methylenetetrahydrofolate reductase (MTHFR) gene [41]. Several studies have investigated the possible role of anti-tumor gene polymorphisms and the prevalence of PCa.…”

Section: Discussionmentioning

confidence: 99%

Polymorphism Analysis of TRAIL Gene and Correlation TRAIL Expression in Prostate Cancer

Mi¹,

Zhu²,

Feng³

2011

Prostate Cancer - Original Scientific Reports and Case Studies

View full text Add to dashboard Cite

MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 Subjects

Abstract: This meta-analysis suggests that the Ala allele of the MnSOD gene was a low-penetrance susceptible gene in PCA development, especially in Caucasians.

Cited by 37 publications

References 26 publications

Plasma Antioxidants, Genetic Variation in SOD2, CAT, GPX1, GPX4, and Prostate Cancer Survival

Plasma Antioxidants, Genetic Variation in SOD2, CAT, GPX1, GPX4, and Prostate Cancer Survival

A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer

Polymorphism Analysis of TRAIL Gene and Correlation TRAIL Expression in Prostate Cancer

Contact Info

Product

Resources

About